Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
Gross C, Banerjee A, Tiwari D, Longo F, White AR, Allen AG, Schroeder-Carter LM, Krzeski JC, Elsayed NA, Puckett R, Klann E, Rivero RA, Gourley SL, Bassell GJ.
Gross C, et al. Among authors: gourley sl.
Neuropsychopharmacology. 2019 Jan;44(2):324-333. doi: 10.1038/s41386-018-0150-5. Epub 2018 Jul 13.
Neuropsychopharmacology. 2019.
PMID: 30061744
Free PMC article.